Dynamic assessment of the pupillary reflex in patients on high-dose opioids

Ulf E Kongsgaard, Gudrun Høiseth, Ulf E Kongsgaard, Gudrun Høiseth

Abstract

Background and aims Pupil size and reaction are influenced by opioids, an effect that is not considered to be affected by opioid tolerance. As clinicians have observed patients on high-dose opioids who exhibited seemingly normal pupil sizes, we wanted to dynamically assess the pupillary reflex in cancer patients on high-dose opioids. Methods We performed a dynamic assessment of the pupillary reflex in cancer patients on high-dose opioids and a control group of healthy volunteers using a portable, monocular, infrared pupillometer. We also performed a clinical examination and measured blood concentrations of opioids and their active metabolites. Results Sixty three patients who were on opioids for 2 months (median time) and on an oral morphine equivalent dose of 250 mg (median dose) were investigated. Most patients used more than one opioid. When correcting for age, pupil size in the group that had received no increase of opioid dose over the last 14 days was not significantly different from pupil size in the healthy volunteer group (p = 0.76), while the group that had increased the dose of opioids differed significantly from healthy volunteers (p = 0.006). We found no statistically significant correlation between total oral morphine equivalents and pupillary reactions or between blood opioid or opioid metabolite concentrations and baseline pupillary changes. Conclusion Pupillary changes do take place in patients on opioids. However, tolerance to these changes occurs when medication is not increased over time. Dynamic pupillometry can give additional information about the degree of tolerance to opioids. Implications These findings elucidate previous misconceptions regarding pupillary effects and tolerance to opioids.

Trial registration: ClinicalTrials.gov NCT02247024.

Keywords: opioids; pain; pupillary reactions; tolerance.

References

    1. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology 2004;101:212–27.
    1. Freye E, Latasch L. [Development of opioid tolerance – molecular mechanisms and clinical consequences]. Anasthesiol Intensivmed Notfallmed Schmerzther 2003;38:14–26.
    1. Gustin H, Akil H. Opioids analgesics. Hardman J, Limbird L, editors. New York: McGraw-Hill, 2001.
    1. Jaffe J, Martin W. Opioid analgesics and antagonists. In: Goodm L, Gilman A, editors. 6th ed. New York: The Macmillan Company, 1980.
    1. Stoelting R, Dierdorf S. Anesthesia and co-existing disease, 2nd ed. New York: Churchill Livingston, 1988.
    1. Reynolds V, Randal L. Morphine and allied drugs, Toronto: University of Toronto Press, 1957.
    1. Mehendale S, Yuan C-S. Clinical pharmaoclogy of opioids: basic pharmacology, 2nd ed. London: Hodder Arnold, 2008.
    1. Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998;81:58–68.
    1. Wildemeersch D, Baeten M, Peeters N, Saldien V, Vercauteren M, Hans G. Pupillary dilation reflex and pupillary pain index evaluation during general anaesthesia: a pilot study. Rom J Anaesth Intensive Care 2018;25:19–23.
    1. Senay EC, Shick JF. Pupillography response to methadone challenge: aid to diagnosis of opioid dependence. Drug Alcohol Depend 1978;3:133–8.
    1. Higgins ST, Stitzer ML, McCaul ME, Bigelow GE, Liebson IA. Pupillary response to methadone challenge in heroin users. Clin Pharmacol Ther 1985;37:460–3.
    1. Tress KH, El-Sobky AA, Aherne W, Piall E. Degree of tolerance and the relationship between plasma morphine concentration and pupil diameter following intervenous heroid in man. Br J Clin Pharmacol 1978;5:299–303.
    1. Tress KH, El-Sobky AA. Pupil responses to intravenous heroin (diamorphine) in dependent and non-dependent humans. Br J Clin Pharmacol 1979;7:213–7.
    1. Kollars JP, Larson MD. Tolerance to miotic effects of opioids. Anesthesiology 2005;102:701.
    1. New York City Detpartment of Health and Mental Hygiene. Morphine Milligram Equivalent (MME) Calculator. Available at: . Accessed: 12 March 2019.
    1. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6–9.
    1. Karinen R, Andersen JM, Ripel A, Hasvold I, Hopen AB, Morland J, Christoffersen AS. Determination of heroin and its main metabolites in small sample volumes of whole blood and brain tissue by reversed-phase liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2009;33:345–50.
    1. Berg T, Lundanes E, Christophersen AS, Strand DH. Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:421–32.
    1. Berg T, Jorgenrud B, Strand DH. Determination of buprenorphine, fentanyl and LSD in whole blood by UPLC-MS-MS. J Anal Toxicol 2013;37:159–65.
    1. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing. conversion dilemmas. J Pain Symptom Manage 2001;21:397–406.
    1. Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manage 2009;38:409–17.
    1. Larson MD, Behrends M. Portable infrared pupillometry: a review. Anesth Anal 2015;120:1242–53.
    1. Knaggs RD, Crighton IM, Cobby TF, Fletcher AJ, Hobbs GJ. The pupillary effects of intravenous morphine, codeine, and tramadol in volunteers. Anesth Anal 2004;99:108–12.
    1. Murray RB, Adler MW, Korczyn AD. The pupillary effects of opioids. Life Sci 1983;33:495–509.
    1. Grunberger J, Linzmayer L, Fodor G, Presslich O, Praitner M, Loimer N. Static and dynamic pupillometry for determination of the course of gradual detoxification of opiate-addicted patients. Eur Arch Psychiatry Clin Neurosci 1990;240:109–12.
    1. Lee HK, Wang SC. Mechanism of morphine-induced miosis in the dog. J Pharmacol Exp Ther 1975;192:415–31.
    1. Pickworth WB, Sharpe LG. Morphine-induced mydriasis and inhibition of pupillary light reflex and fluctuations in the cat. J Pharmacol Exp Ther 1985;234:603–6.
    1. Murray RB, Loughnane MH. Infrared video pupillometry: a method used to measure the pupillary effects of drugs in small laboratory animals in real time. J Neurosci Methods 1981;3:365–75.
    1. Larson MD. Mechanism of opioid-induced pupillary effects. Clin Neurophysiol 2008;119:1358–64.
    1. Rollins MD, Feiner JR, Lee JM, Shah S, Larson M. Pupillary effects of high-dose opioid quantified with infrared pupillometry. Anesthesiology 2014;121:1037–44.
    1. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005;29(5 Suppl):S90–103.
    1. Lotsch J, Skarke C, Schmidt H, Grosch S, Geisslinger G. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology 2001;95:1329–38.
    1. Fotiou DF, Brozou CG, Tsiptsios DJ, Fotiou A, Kabitsi A, Nakou M, Giantselidis C, Goula A. Effect of age on pupillary light reflex: evaluation of pupil mobility for clinical practice and research. Electromyogr Clin Neurophysiol 2007;47: 11–22.
    1. Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000;19:200–8.
    1. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 2002;16: 9–28.
    1. Farrell M. Opiate withdrawal. Addiction (Abingdon, England) 1994;89:1471–5.
    1. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35:253–9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel